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Influenza A (FluA) and B (FluB) viruses are responsible for hundreds of thousands of deaths each year, especially among high5risk population groups (infants, elderly, people with immune deficiency). 1 The prophylactic, yearly reformulated vaccine and two classes of drugs are currently the only available anti5influenza therapeutic options. 2 The first class is represented by the M2 viral ion5channel inhibitors and includes the adamantanes (i.e., amantadine and rimantadine). The M2
inhibitors are only effective against FluA, and a significant increase of virus resistance to this class of compounds has been observed in recent years. Currently, all circulating FluA virus strains appear to be resistant to M2 inhibitors. 3, 4 The second class of antiviral compounds targets the viral neuraminidase (NA). NA inhibitors block the release of virions after budding from the host cell. 5, 6 zanamivir was the first NA inhibitor commercially developed. 7 It was discovered in 1989 using a target5guided design and exemplifies one of the first successful uses of this approach in drug discovery. The computational approach was based on the GRID force field, developed at the University of Oxford by Peter Goodford. 8 The discovery of zanamivir was published in 1993 with more than a thousand citations to date. Although limited by poor bioavailability, zanamivir is still on the market, even though the orally active oseltamivir is usually preferred. Nowadays, NA inhibitors represent the only class of antiviral drugs to treat both FluA and FluB infections.
However, resistance episodes were recently observed for oseltamivir in several Flu strains. 3, 9 For these reasons, increasing efforts have been devoted to the identification of novel antiviral strategies. 10 Recently, the viral polymerase attracted attention as a new target for the development of novel anti5influenza compounds. 11518 This protein is a heterotrimeric complex formed by the PB1, PB2, and PA subunits. The correct non5covalent assembly of the three subunits is essential for viral RNA synthesis. 19 It is known that all three subunits, PB1, PB2, and PA, are necessary for both transcription and replication of the viral genome. 20 ,21 PB1 possesses polymerase activity, PB2 is responsible for cap5binding of host cell pre5mRNAs, whereas PA contains the endonuclease domain and is implicated in RNA replication by cleaving capped host pre5 RNAs. The main advantage in exploiting the viral RNA polymerase as a target for drug design is that, in contrast to the viral glycoproteins, it is highly conserved among different viral strains, 19 and thus RNA polymerase inhibitors are expected to possess a broad antiviral activity.
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Just as the rational design of NA inhibitors became possible once the neuraminidase X5ray structure became available, today, the design of potential inhibitors of the influenza virus RNA polymerase is facilitated by the recent elucidation of its structure at atomic level. 23525 In particular, two recently published X5ray structures of a C5terminal domain of PA bound to an N5terminal peptide of PB1 23, 24 have clarified the molecular details of the PA5PB1 interaction: an N5terminal 3 10 helix from PB1 binds into a hydrophobic groove in the C5terminus of PA, with relatively few residues driving the PA5PB1 binding. More recently, the PB15PB2 interaction domain was also explored by X5ray crystallography. 25 Although the use of PB15PB2 interface as a target for the design of possible RdRP inhibitors is still under investigation, 26 the tailored design of small molecules that inhibit the formation of the PA5PB1 complex formation has already been demonstrated to be a promising strategy towards a new class of anti5influenza drugs. 11518 Attempts to inhibit the formation of the PA5PB1 complex using peptides have also been reported. 27, 28 However, whether it is better to use peptides or small molecules to inhibit protein5protein interaction is still a topic of much debate. On the one hand, peptides can better mimic the protein interaction showing high target selectivity and affinity. 29 On the other hand, small molecules usually possess better pharmacokinetic properties.
Furthermore, there are only very few examples of unmodified peptides that have reached the market as drugs, due to their proteolytic instability or lack of cell permeation.
Chemically, compound 1 is a pyrazolo [1,55a] pyrimidine carrying a 5cyclopentathiophene carboxamide moiety at the C53′ position, a phenyl substituent at the C55′ position and a difluoromethyl group at the C57′ position ( Figure 1 ). In this study, the thiophenecarboxamide moiety was preserved since it was recently identified to be a promising scaffold for anti5Flu
compounds. 16 As a first attempt, the pyrazolo [1,55a] pyrimidine (scaffold I, Table 1 ) was also maintained, while the difluoromethyl group, the cyclopentathiophene amide moiety, and the phenyl substituent at the C55′ position were modified (compounds 2 6, Table 1 ). The selective incorporation of fluorine atom(s) or fluoroalkyl group(s) (such as CF 3 , CHF 2 , and CH 2 F) into organic molecules has become a trend in life5sciences5related applications. 30, 31 Many studies have
shown that a fluorine atom(s) or fluoroalkyl group(s) can bring several beneficial effects in bioactive molecules, such as the enhancement of metabolic stability, lipophilicity, bioavailability and binding affinity. 32539 Among the fluoroalkyl groups, the difluoromethyl (CHF 2 ) group in compound 1 is of particular interest, because it is known to be isosteric and isopolar to a carbinol (CH 2 OH) unit and, despite its lipophilic nature, can also act as a hydrogen bond donor. 40 By replacing the difluoromethyl group with the trifluoromethyl group (compounds 2, 4 6, Table 1 ) we wanted to investigate whether or not the hydrogen5bond donor capability of the CHF 2 group could be crucial in the interaction of compound 1 with PA.
Recent studies on new RdRP inhibitors bearing a cycloheptathiophene moiety revealed that the size of the aliphatic ring fused with thiophene was critical for the inhibitory effect. 16 Therefore, we also tried to increase the size of the ring by replacing the cyclopentane with a cyclohexane ring (compounds 3 6, Table 1 ).
The last modification for scaffold I was the introduction of a hydrophobic or a hydrophilic substituent at the para5position of the phenyl ring (compounds 5 and 6 in Table 1 , respectively).
The major structural modifications were performed by replacement of the pyrazolo [1, 55 a]pyrimidine (scaffold I, 
Synthesis of polyamido derivatives.
A number of derivatives of compound 10 were also synthesized. The polyamido5sulfonamides 18 22 were prepared according to literature procedures or their modification (Scheme 3). Thus, the nucleophilic attack of either 5butylamine or aniline at C54 of isatoic anhydride, followed by the elimination of carbon dioxide from the carbamic acid intermediate, gave the anthranilamides 16a b, respectively, in excellent yield.
45,46
The condensation of the anthranilamides 16a b with 45substituted 35bromobenzoyl chloride in refluxing toluene, in the presence of triethylamine, afforded the bisamide 17a c. Butyllithium5 promoted bromine5lithium exchange in THF at -78 °C, followed by addition of sulfur dioxide at -60 °C, converted the bromo derivatives 17a c in the corresponding lithium sulfinate. 46 The latter were treated with 5chlorosuccinimide to give the expected sulfonyl chlorides, which were smoothly converted into the target sulfonamide 10 and 18 22 in 20-25% overall yield by reaction with the suitable amine in acetone at 50 °C.
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BIOLOGICAL EVALUATION
Our hit compound 1, previously tested as provided from the vendor, 13 was synthesized and retested, giving comparable results ( Table 1 ).
The synthesized compounds 2 8 and the acquired compounds 9 12 were tested in ELISA to determine their inhibitory activity on PA5PB1 interaction. The PB1(1-15)-Tat peptide 13 was used as a positive control. In addition, we evaluated the ability of the compounds to inhibit the activity of
FluA RNA polymerase by a minireplicon assay in transfected HEK 293T cells, 49 while the antiviral activity in FluA virus5infected MDCK cells was evaluated by plaque reduction assays (PRA) using the A/PR/8/34 (PR8) strain. In these assays, Ribavirin (RBV), a known inhibitor of RNA viruses polymerase, 50 was used as a positive control. Moreover, MTT cytotoxicity assays in MDCK and HEK293T cell lines using RBV as a reference compound were also performed to exclude cytotoxic compounds. Antiviral activity and toxicity data for all the tested compounds are reported in Table 1 .
Modifications made using scaffold I (compounds 2 6) did not give any significant improvement in the antiviral activity. However, a comparison of the results for 1 and 2, differing in the fluorinated substituent only, reveals that the H5bond donor capability of the CHF 2 moiety seems not to be critical for inhibition. On the other hand, the replacement of the cyclopentathiophene moiety of compound 1 with the cyclohexathiophene moiety to give compound 3 induced a three5fold increase of the IC 50 value in the ELISA and of the EC 50 value in the FluA minireplicon assay, although the activity of compound 3 against FluA replication is very similar to those of compounds 1 and 2.
Surprisingly, the additional substitution of CHF 2 with CF 3 (compound 4) led to a decreased activity in all the tests performed. When a methyl group was added in the para5position of the phenyl ring of compound 4 to give compound 5, a decrease of the IC 50 value in the ELISA and the EC 50 value in the FluA minireplicon assay was observed. The inhibitory efficacy in PRA was also slightly improved, even though compound 5 resulted to be a weaker inhibitor with respect to the hit compound. This finding is in agreement with our previous results, 13, 16 indicating that hydrophobic interactions are favorable in designing RdRP inhibitors. When a polar substituent such as a methoxy group was introduced instead of a methyl group to give compound 6, a less active compound in the ELISA assay was obtained. This compound also resulted to be toxic in cell5based assays.
Compound 6 appeared to be the only cytotoxic compound in the scaffold I series.
Even though the optimization of the scaffold I did not bring successful results, the replacement of the pyrazolo [1,55a] pyrimidine with a triazolopyrimidine (scaffold II) to give compound 7 in Table 1 proved to be very effective. Indeed, compound 7, which bears the CF 3 substituent and cyclohexane, resulted to be about 35fold more efficient than compound 1 in inhibiting both PA5PB1 complex formation and viral replication. Purification difficulties were encountered during the synthesis of the cyclopentane analogue, and thus further investigation of this scaffold would require an optimization of the reaction conditions. The replacement of the pyrazolo [1,55a] pyrimidine with a pyridine to give scaffold III in Table 1 led to a cytotoxic compound (compound 8) with no activity according to the ELISA.
Concerning the four compounds acquired following the scaffold hopping approach, the polyamido derivative 10 was found to be a good RdRP inhibitor. Indeed, compound 10 not only exhibited an inhibitory activity against the PA5PB1 interaction comparable to that of the hit compound, but also proved to be 45fold more potent than compound 1 in blocking FluA replication. Of the other three acquired compounds (9, 11, 12), compounds 9 and 11 resulted to be cytotoxic, although an IC 50 of 35.1 ± 4.3 GM was obtained for compound 9 in the ELISA assays. Thus, these compounds were not further investigated. Compound 12 was found to be not cytotoxic, but also inactive. To further investigate the new polyamido scaffold, compound 10 and five analogues were synthesized. Tests on the resynthesized compound 10 gave comparable inhibitory effects to those obtained using the The derivatives of compound 10 were aimed at tuning the hydrophobicity and their size.
Compounds 18 and 19, which differ from the reference compound for the lack of one or all methyl substituents, respectively, were synthesized first. Methyl groups are not likely to be involved in specific interaction with protein residues but, enhancing the overall hydrophobicity, could play a role in RdRP inhibitory efficacy, since it is known that the PA cavity is mainly hydrophobic.
13,16, 51
Compounds 20 and 21 were then synthesized by adding an additional aromatic ring to the two edges of compound 10. These compounds served to preliminary investigate whether larger and more hydrophobic compounds could display a similar inhibitory activity. To mimic a "peptide5like"
feature, an amide linkage was used, which was typical of the polyamido scaffold of compound 10.
Finally, compound 22 was synthesized as an attempt to explore the effect of the introduction of polar substituents. The structures and biological data for the five polyamido derivatives are reported in Table 2 .
Removal of one (18) or all (19) methyl groups gave results comparable to the lead 10, so we assumed that their role was not crucial for preservation of antiviral activity. However, compound 19 resulted the most efficient in inhibiting the PA5PB1 interaction, giving an IC 50 value of 9.2 ± 1.5 GM in the ELISA.
Addition of a further hydrophobic moiety on the sulfonamide part, as in compound 20, did not affect cytotoxicity, but had a detrimental effect on the antiviral activity. On the other hand, replacement of the 5butyl group in the terminal amido moiety with a phenyl ring, as in compound 21, resulted in toxicity in MCDK cells. This compound is only modestly active in ELISA, thus its good antiviral activity in PRA could be due to its toxicity profile. Finally, compound 22, which held a hydroxyl group in para5position of sulfonamide portion, showed a dramatic decrease in activity. To test the specificity of the inhibitory activity, the four most active compounds (compounds 7, 10, In contrast, compound AL5, previously shown to inhibit the interactions between the HCMV DNA polymerase subunits, 53 did interfere with UL545UL44 binding (see Figure S1 in the Supporting Material).
The antiviral effect of the four most active compounds 7, 10, 18, and 19 was finally investigated against a number of clinical isolates of FluA other than PR8, of both H1N1 and H3N2 subtypes, including a swine5derived pandemic strain and an oseltamivir5resistant virus. In addition, the same compounds were also tested for their ability to inhibit the replication of two FluB strains (B/Lee/40 and B/Malaysia/2506/04). The hit compound 1 was also included as a reference compound. The biological data for the evaluation of broad5spectrum activity are reported in Table 3 . Preliminary ADME studies (water solubility, permeability and metabolic stability) were performed for compounds 7 and 19, being the most promising compounds. Methods for these studies are reported in the Supporting Material. Concerning water solubility, compounds 7 and 19 showed a solubility of 2.4 and 1.0 Gg/ml, respectively, measured by NMR as previously reported.
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A preliminary PAMPA permeability assay 55 was also performed, with compound 19 resulting to be in the range of medium/high permeability, while compound 7 resulted to fall in the "low permeability" class. Finally, metabolic stability was evaluated in HLM after 30 minutes incubation.
Compound 7 was metabolically stable in HLM, while compound 19 underwent through aromatic hydroxylation at the benzenesulfonamide moiety, to give the monohydroxylated metabolite. After 30 minutes, substrate was at 50% abundance. The metabolic stability of compound 1 was also measured and the aliphatic hydroxylation at the cyclopentane ring was observed, with compound 1 reduced to 37%, highlighting the better stability of compounds 19 and 7 with respect to the hit compound. Although the reported ADME profile is still very preliminary, it suggests that both compounds are too lipophilic, and further lead optimization will be aimed at finding the best compromise between lipophilicity (which is important for activity) and solubility.
PHARMACOPHORE GENERATION
Our recent studies, aimed at discovering new small5molecule antiviral compounds targeting the PA5 PB1 subunit interaction of the viral RdRP, led to the identification of five compounds that possess very different chemical structures but similar inhibitory activity against the replication of FluA and FluB. Compounds 7 and 19 were found to be the most potent RdRP inhibitors. Three other compounds were previously reported by some of us to be active against the influenza polymerase complex. 13, 16 The chemical structures of the five compounds are reported in Figure 3 . When a number of active compounds with different scaffolds are identified, the most natural step to advance their improvement is to attempt to generate a possible pharmacophore. A pharmacophoric model was therefore generated by alignment of the five compounds using the FLAPpharm algorithm.
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The pharmacophoric model is reported in Figure 4A , while the structures of the five compounds aligned to the pharmacophore are reported in Figure 4B5F . As shown in Figure 4A 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 the activity. In Figure 4 , the green MIFs are related to hydrophobic interactions, while blue and red MIFs refer to H5bond donor and H5bond acceptor interactions, respectively. The same color5code is also used for the pharmacophoric points.
According to the pharmacophore GRID MIFs, extended and quite planar hydrophobic moieties represent a common feature among the RdRP inhibitors (green solid surface in Figure 4A ). In addition, one H5bond donor and one H5bond acceptor MIF emerged upon alignment of the five compounds (blue and red solid surfaces in Figure 4A , respectively). Figure S2 in the Supporting Material). This result, in addition to the variability of the NH groups previously discussed, suggests that the H5bond acceptor GRID MIF region could be less critical for binding.
CONCLUSIONS
In recent years, the viral RdRP has proved to be an attractive target in the design of small molecules capable of inhibiting influenza virus replication. A few RdRP inhibitors have been published so far 20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 compound 7, a 35fold more potent PA5PB1 inhibitor was obtained with respect to compound 1, inhibiting the physical interaction between the two viral subunits with an IC 50 value of 7.5 ± 0.7
SM. This finding suggests that the synthesis of new derivatives having a more linear shape might be helpful to improve the inhibitory effect. As a result of the scaffold hopping approach, we identified the sulphonamide compound 10, which was acquired and assayed. Despite the significantly different polyamido scaffold, compound 10 produced a good RdRP inhibitory effect targeting the PA5PB1 complex. The synthesis of the slightly different compound 19 led to an inhibitory activity comparable to that of compound 7. Both compounds 7 and 19 were found to be not cytotoxic in the two cell lines used for testing and they were also able to inhibit a number of FluA and FluB strains.
The discovery of two very different scaffolds with similar activities prompted us to generate a pharmacophoric model by also taking into consideration three other recently published RdRP inhibitors that have been proven to be active against FluA and FluB. Based on this model, all the selected active compounds were shown to possess an extended and quite planar hydrophobic moiety. In addition, the alignment of the molecular structures revealed that they have a common carbonyl group which is able to act as a H5bond acceptor, and in the opposite site an NH group of varying chemical nature which is able to act as a H5bond donating group. The proposed The previously published compound 1 was selected as a hit compound for further optimization by two complementary approaches: 1) the design and the synthesis of derivatives of compound 1, to investigate the structural features that might be responsible for PA5PB1 complex disruption; 2) a scaffold hopping approach to identify novel scaffolds for PA5PB1 complex inhibitors. In the modulation of the chemical structure of compound 1, the thiophene535carboxamide moiety, which emerged as a favorable scaffold in the design of RdRP inhibitors, 16 was always preserved.
However, when the pyrazolo [1,55a] pyrimidine was replaced with a triazolopyrimidine to give 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 pharmacophore could be useful to design novel RdRP inhibitors, focusing the attention on similar interaction capabilities rather than on similar scaffolds. was prepared. All protomeric forms in at least 20% abundance at pH 7.4 were generated for each compound using the MoKa algorithm. 57,58 A number of 50 conformers for each protomer was also generated to mimic flexibility. Then a ligand5based virtual screening was performed using compound 1 as a template. Thus, in this study FLAP algorithm was not used to perform virtual screening, but only to re5score the best hits found by a structure5based approach 13 for their similarity to our hit compound. The 293 candidates were ranked by the GloB5Sum descriptor, and four compounds having a similarity score >1.5 and different scaffolds were selected. Their availability, cost, and druggability were also taken into consideration. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 chloride with 5butyl 35aminophenylcarbamate followed by amino group deprotection upon heating at 140 °C. Tetrahydrofuran was distilled from sodium wire after the characteristic blue color of generated sodium biphenyl ketyl (benzophenone5sodium "radical anion") had been found General procedure to prepare amides 1 8.
Oxalyl chloride (1.5 mmol) was added to a solution of the suitable carboxylic acid 15a b (1.0 mmol) and DMF (0.1 mmol) in dry DCM (3 mL) and the mixture was kept 2 h at 25 °C while stirring. After the solvent was evaporated at reduced pressure, the residue was dissolved in dry dichloromethane (4 mL), the appropriate 25amino5thiophene535carboxamide (1.0 mmol) and pyridine (2.0 mmol) were added and the mixture was made to react at room temperature for 16 h.
The solvent was evaporated at reduced pressure and the residue was washed in sequence with diethyl ether (2 × 5 mL), 2 M sodium hydroxide, 2 M hydrochloric acid, and water. Finally, the residue was dried under vacuum and chromatographed on silica gel (eluent, 9:1 dichloromethane/methanol mixture). 
.
General procedure to prepare polyamido products 10, 18 22.
47,48
Butyllithium (20.3 mL, 1.48 M in hexanes, 30 mmol) was added drop5wise at -75 °C to a solution of the appropriate bromo derivative (17a c) (10 mmol) in tetrahydrofuran (100 mL) and the mixture was made to react for 10 min, under stirring, before the bath temperature was allowed to rise to -60 °C. Sulfur dioxide was bubbled into the mixture until its pH value reached 657. The cold bath was removed and the temperature was allowed to rise to 25 °C. Hexane (20 mL) was added and the formed white precipitate was filtered, washed with hexane and dried at 50 °C. The dry solid was suspended in dichloromethane (20 mL), the mixture was cooled at 0 °C and 5chlorosuccinimide
(1.9 g, 14 mmol, 1.4 eq) was added in portions. The mixture was made to react for 15 min at 0 °C, while stirring, and then it was kept at room temperature for further 25 min. The resulting suspension was filtered off on celite, the solvent was evaporated at reduced pressure and the solid residue was solved in acetone (20 mL). Triethylamine (1.4 mL, 10 mmol) and the suitable amine (10 mmol)
were added and the mixture was kept at room temperature for 12 h while stirring. After solvent evaporation at reduced pressure, chromatography of the residue on silica gel allowed to collect the pure product. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60 Activity of the compounds in ELISA PA5PB1 interaction assays. The IC 50 value represents the compound concentration that reduces the interaction between PA and PB1 by 50%.
b Activity of the compounds in minireplicon assays. The EC 50 value represents the compound concentration that reduces the catalytic activity of FluA polymerase by 50%.
c Activity of the compounds in plaque reduction assays with the FluA PR8 strain. The EC 50 value represents the compound concentration that inhibits 50% of plaque formation.
d Activity of the compounds in MTT assays. The CC 50 value represents the compound concentration that causes a decrease of cell viability of 50%. All the reported values represent the means ± SD of data derived from at least three independent experiments in duplicate. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
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Activity of the compounds in plaque reduction assays with the different FluA and FluB strains. The EC 50 value represents the compound concentration that inhibits 50% of plaque formation. All the reported values represent the means ± SD of data derived from at least three independent experiments in duplicate. Table 1.   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Scheme 2. Table 2.   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57 58 59
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